Shots:

• Shoreline to receive $45M up front in cash and is eligible to receive R&D funding- milestones along with royalties- following the achievement of certain milestones
• The companies will jointly develop cell therapies for four targets- with an option to further expand the collaboration. BeiGene will lead the clinical development globally while Shoreline will be responsible for clinical manufacturing
• BeiGene to get WW commercial rights with Shoreline having an option to retain US and Canadian commercialize rights for two targets out of four. Additionally- BeiGene gets an option to acquire an equity stake in Shoreline in its next round of equity financing for specified conditions

Ref: Business Wire | Image: PR Newswire